Skip to content

Join Newsletter

Shop

Search For:

What’s Melanoma?
- Understanding Melanoma
Patient Care
Education
Research & Science
Our Work
How to Help
Events
About Us

Donate

More

Shop Donate

What’s Melanoma?
- Understanding Melanoma
Patient Care
Education
Research & Science
Our Work
How to Help
Events
About Us

March 31, 2026

2025 Annual Report: Reflecting on the Impact of Your Generosity

View Stewardship Report

Popular Resources

Cutaneous Melanoma Patient Guide Stages 0-1 Cutaneous Melanoma Patient Guide Stages 2-3 Melanoma Research Foundation – Melanoma Patient Forum Melanoma Research Foundation Clinical Trial Finder Treatment Center Finder - Melanoma Research Foundation

Legacy of Progress Endowment Fund

MRF Merch – Shop for a Cause

Genetic characterization of congenital melanocytic nevi and malignant melanoma

Erik Geiger

Medical Student Award

Yale University School of Medicine

Medical Student Award – Erik Geiger

Stay Updated With the MRF.

Join Our Newsletter

Join Newsletter

I AM...

New to Melanoma
Patient & Survivor
Caregiver
Research & Science
Advocate
Donor
Corporate Partner

Get Engaged

Donate Now
Shop the MRF
Ways to Give
Our Newsletter
Attend an Event
Join Patient Forum
View the Newsroom
Grants & RFPs

Explore

What’s Melanoma?
Patient Care
Education
Research & Science
Our Work
How to Help
Events
About Us

A 501(c)(3) Non-Profit Organization.

The Melanoma Research Foundation (MRF), a 501(c)(3) non-profit organization, is leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy.

© Copyright 2026 Melanoma Research Foundation (MRF)

Privacy Policy
Terms of Use

THE INFORMATION ON THIS WEBSITE IS FOR INFORMATION PURPOSES ONLY AND IS NOT A RECOMMENDATION OR ENDORSEMENT OF ANY DRUG, DEVICE OR TREATMENT OR THAT ANY PARTICULAR DRUG, DEVICE OR TREATMENT IS SAFE, APPROPRIATE OR EFFECTIVE FOR YOU. QUESTIONS REGARDING ANY DRUG, DEVICE OR TREATMENT SHOULD BE DIRECTED TO YOUR HEALTHCARE PROVIDER.